Roivant Sciences Ltd
(FRA:87S)
€
11.525
0.15 (1.32%)
Market Cap: 8.62 Bil
Enterprise Value: 3.56 Bil
PE Ratio: 2.21
PB Ratio: 1.78
GF Score: 60/100 Roivant Sciences Ltd at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023 / 05:00PM GMT
Release Date Price:
€8.95
(+5.29%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP
Great. Well, thanks to the team from Roivant that's here today. Richard Pulik, CFO; Mayukh Sukhatme, Chief Investment Officer.
Questions & Answers
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP
And maybe just to start, we can talk about kind of a brief overview of the business and what you view as key programs that will shape the story over the next 12 to 24 months?
Mayukh Sukhatme
Roivant Sciences Ltd. - President & CIO
Sure. Yes. So for those of you who may be less familiar with Roivant as a company or a public company, a little over $7 billion in market cap, a little less than $2 billion in cash. We have a marketed product in VTAMA and a series of late stage, mid late-stage clinical programs, including a first-in-class TL1A antibody, an FcRn portfolio via Immunovant, a TYK2 JAK1, and many, many other things.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot